<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:27 -0700</creation_date>
  <update_date>2013-05-27 11:14:53 -0600</update_date>
  <accession>HMDBP00932</accession>
  <secondary_accessions>
    <accession>6220</accession>
    <accession>HMDBP03325</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>Dimethylallyltranstransferase</synonym>
    <synonym>FPP synthase</synonym>
    <synonym>FPS</synonym>
    <synonym>Farnesyl diphosphate synthase</synonym>
    <synonym>Geranyltranstransferase</synonym>
    <synonym>(2E,6E)-farnesyl diphosphate synthase</synonym>
  </synonyms>
  <gene_name>FDPS</gene_name>
  <general_function>Involved in isoprenoid biosynthetic process</general_function>
  <specific_function>Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.
</specific_function>
  <pathways>
    <pathway>
      <name>geranyl diphosphate biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>farnesyl diphosphate biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Terpenoid backbone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00900</kegg_map_id>
    </pathway>
    <pathway>
      <name>Influenza A</name>
      <smpdb_id/>
      <kegg_map_id>map05164</kegg_map_id>
    </pathway>
    <pathway>
      <name>HTLV-I infection</name>
      <smpdb_id/>
      <kegg_map_id>map05166</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00250</accession>
      <name>Pyrophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00961</accession>
      <name>Farnesyl pyrophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01120</accession>
      <name>Dimethylallylpyrophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01285</accession>
      <name>Geranyl-PP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01347</accession>
      <name>Isopentenyl pyrophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02142</accession>
      <name>Phosphoric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14427</accession>
      <name>Pamidronate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14543</accession>
      <name>Zoledronate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14848</accession>
      <name>Ibandronate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15022</accession>
      <name>Risedronate</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>primary metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>isoprenoid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>isoprenoid biosynthetic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrion</description>
      <go_id>GO:0005739</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>nucleus</description>
      <go_id>GO:0005634</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>dimethylallyltranstransferase activity</description>
      <go_id>GO:0004161</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>geranyltranstransferase activity</description>
      <go_id>GO:0004337</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cholesterol biosynthetic process</description>
      <go_id>GO:0006695</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>farnesyl diphosphate biosynthetic process</description>
      <go_id>GO:0045337</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>geranyl diphosphate biosynthetic process</description>
      <go_id>GO:0033384</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>virus-host interaction</description>
      <go_id>GO:0019048</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>1</chromosome_location>
    <locus>1q22</locus>
    <gene_sequence>&gt;1260 bp
ATGCCCCTGTCCCGCTGGTTGAGATCTGTGGGGGTCTTCCTGCTGCCAGCCCCCTACTGG
GCACCCCGGGAGAGGTGGCTGGGTTCCCTACGGCGGCCCTCCCTGGTGCACGGGTACCCA
GTCCTGGCCTGGCACAGTGCCCGCTGCTGGTGCCAAGCGTGGACAGAGGAACCTCGAGCC
CTTTGCTCCTCCCTCAGAATGAACGGAGACCAGAATTCAGATGTTTATGCCCAAGAAAAG
CAGGATTTCGTTCAGCACTTCTCCCAGATCGTTAGGGTGCTGACTGAGGATGAGATGGGG
CACCCAGAGATAGGAGATGCTATTGCCCGGCTCAAGGAGGTCCTGGAGTACAATGCCATT
GGAGGCAAGTATAACCGGGGTTTGACGGTGGTAGTAGCATTCCGGGAGCTGGTGGAGCCA
AGGAAACAGGATGCTGATAGTCTCCAGCGGGCCTGGACTGTGGGCTGGTGTGTGGAACTG
CTGCAAGCTTTCTTCCTGGTGGCAGATGACATCATGGATTCATCCCTTACCCGCCGGGGA
CAGATCTGCTGGTATCAGAAGCCGGGCGTGGGTTTGGATGCCATCAATGATGCTAACCTC
CTGGAAGCATGTATCTACCGCCTGCTGAAGCTCTATTGCCGGGAGCAGCCCTATTACCTG
AACCTGATCGAGCTCTTCCTGCAGAGTTCCTATCAGACTGAGATTGGGCAGACCCTGGAC
CTCCTCACAGCCCCCCAGGGCAATGTGGATCTTGTCAGATTCACTGAAAAGAGGTACAAA
TCTATTGTCAAGTACAAGACAGCTTTCTACTCCTTCTACCTTCCTATAGCTGCAGCCATG
TACATGGCAGGAATTGATGGCGAGAAGGAGCACGCCAATGCCAAGAAGATCCTGCTGGAG
ATGGGGGAGTTCTTTCAGATTCAGGATGATTACCTTGACCTCTTTGGGGACCCCAGTGTG
ACCGGCAAAATTGGCACTGACATCCAGGACAACAAATGCAGCTGGCTGGTGGTTCAGTGT
CTGCAACGGGCCACTCCAGAACAGTACCAGATCCTGAAGGAAAATTACGGGCAGAAGGAG
GCTGAGAAAGTGGCCCGGGTGAAGGCGCTATATGAGGAGCTGGATCTGCCAGCAGTGTTC
TTGCAATATGAGGAAGACAGTTACAGCCACATTATGGCTCTCATTGAACAGTACGCAGCA
CCCCTGCCCCCAGCCGTCTTTCTGGGGCTTGCGCGCAAAATCTACAAGCGGAGAAAGTGA
</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>419</residue_number>
    <molecular_weight>48275.03</molecular_weight>
    <theoretical_pi>6.153</theoretical_pi>
    <pfams>
      <pfam>
        <name>polyprenyl_synt</name>
        <pfam_id>PF00348</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Farnesyl pyrophosphate synthase
MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCWCQAWTEEPRA
LCSSLRMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAI
GGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRG
QICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLD
LLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLE
MGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKE
AEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK</protein_sequence>
  </protein_properties>
  <genbank_protein_id>158255604</genbank_protein_id>
  <uniprot_id>P14324</uniprot_id>
  <uniprot_name>FPPS_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1YQ7</pdb_id>
    <pdb_id>1YV5</pdb_id>
    <pdb_id>1ZW5</pdb_id>
    <pdb_id>2F7M</pdb_id>
    <pdb_id>2F89</pdb_id>
    <pdb_id>2F8C</pdb_id>
    <pdb_id>2F8Z</pdb_id>
    <pdb_id>2F92</pdb_id>
    <pdb_id>2F94</pdb_id>
    <pdb_id>2F9K</pdb_id>
    <pdb_id>2OPM</pdb_id>
    <pdb_id>2OPN</pdb_id>
    <pdb_id>2QIS</pdb_id>
    <pdb_id>2RAH</pdb_id>
    <pdb_id>2VF6</pdb_id>
    <pdb_id>3B7L</pdb_id>
    <pdb_id>3CP6</pdb_id>
    <pdb_id>3N1V</pdb_id>
    <pdb_id>3N1W</pdb_id>
    <pdb_id>3N3L</pdb_id>
    <pdb_id>3N45</pdb_id>
    <pdb_id>3N46</pdb_id>
    <pdb_id>3N49</pdb_id>
    <pdb_id>3N5H</pdb_id>
    <pdb_id>3N5J</pdb_id>
    <pdb_id>3N6K</pdb_id>
    <pdb_id>3RYE</pdb_id>
    <pdb_id>3S4J</pdb_id>
    <pdb_id>4DEM</pdb_id>
    <pdb_id>4H5C</pdb_id>
    <pdb_id>4H5D</pdb_id>
    <pdb_id>4H5E</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AK291084</genbank_gene_id>
  <genecard_id>FDPS</genecard_id>
  <geneatlas_id>FDPS</geneatlas_id>
  <hgnc_id>HGNC:3631</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Nomura N, Miyajima N, Sazuka T, Tanaka A, Kawarabayasi Y, Sato S, Nagase T, Seki N, Ishikawa K, Tabata S: Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1. DNA Res. 1994;1(1):27-35.</reference_text>
      <pubmed_id>7584026</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gregory SG, Barlow KF, McLay KE, Kaul R, Swarbreck D, Dunham A, Scott CE, Howe KL, Woodfine K, Spencer CC, Jones MC, Gillson C, Searle S, Zhou Y, Kokocinski F, McDonald L, Evans R, Phillips K, Atkinson A, Cooper R, Jones C, Hall RE, Andrews TD, Lloyd C, Ainscough R, Almeida JP, Ambrose KD, Anderson F, Andrew RW, Ashwell RI, Aubin K, Babbage AK, Bagguley CL, Bailey J, Beasley H, Bethel G, Bird CP, Bray-Allen S, Brown JY, Brown AJ, Buckley D, Burton J, Bye J, Carder C, Chapman JC, Clark SY, Clarke G, Clee C, Cobley V, Collier RE, Corby N, Coville GJ, Davies J, Deadman R, Dunn M, Earthrowl M, Ellington AG, Errington H, Frankish A, Frankland J, French L, Garner P, Garnett J, Gay L, Ghori MR, Gibson R, Gilby LM, Gillett W, Glithero RJ, Grafham DV, Griffiths C, Griffiths-Jones S, Grocock R, Hammond S, Harrison ES, Hart E, Haugen E, Heath PD, Holmes S, Holt K, Howden PJ, Hunt AR, Hunt SE, Hunter G, Isherwood J, James R, Johnson C, Johnson D, Joy A, Kay M, Kershaw JK, Kibukawa M, Kimberley AM, King A, Knights AJ, Lad H, Laird G, Lawlor S, Leongamornlert DA, Lloyd DM, Loveland J, Lovell J, Lush MJ, Lyne R, Martin S, Mashreghi-Mohammadi M, Matthews L, Matthews NS, McLaren S, Milne S, Mistry S, Moore MJ, Nickerson T, O'Dell CN, Oliver K, Palmeiri A, Palmer SA, Parker A, Patel D, Pearce AV, Peck AI, Pelan S, Phelps K, Phillimore BJ, Plumb R, Rajan J, Raymond C, Rouse G, Saenphimmachak C, Sehra HK, Sheridan E, Shownkeen R, Sims S, Skuce CD, Smith M, Steward C, Subramanian S, Sycamore N, Tracey A, Tromans A, Van Helmond Z, Wall M, Wallis JM, White S, Whitehead SL, Wilkinson JE, Willey DL, Williams H, Wilming L, Wray PW, Wu Z, Coulson A, Vaudin M, Sulston JE, Durbin R, Hubbard T, Wooster R, Dunham I, Carter NP, McVean G, Ross MT, Harrow J, Olson MV, Beck S, Rogers J, Bentley DR, Banerjee R, Bryant SP, Burford DC, Burrill WD, Clegg SM, Dhami P, Dovey O, Faulkner LM, Gribble SM, Langford CF, Pandian RD, Porter KM, Prigmore E: The DNA sequence and biological annotation of human chromosome 1.  Nature. 2006 May 18;441(7091):315-21.</reference_text>
      <pubmed_id>16710414</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wilkin DJ, Kutsunai SY, Edwards PA: Isolation and sequence of the human farnesyl pyrophosphate synthetase cDNA. Coordinate regulation of the mRNAs for farnesyl pyrophosphate synthetase, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and 3-hydroxy-3-methylglutaryl coenzyme A synthase by phorbol ester. J Biol Chem. 1990 Mar 15;265(8):4607-14.</reference_text>
      <pubmed_id>1968462</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sheares BT, White SS, Molowa DT, Chan K, Ding VD, Kroon PA, Bostedor RG, Karkas JD: Cloning, analysis, and bacterial expression of human farnesyl pyrophosphate synthetase and its regulation in Hep G2 cells. Biochemistry. 1989 Oct 3;28(20):8129-35.</reference_text>
      <pubmed_id>2690933</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lefebvre L, Vanderplasschen A, Ciminale V, Heremans H, Dangoisse O, Jauniaux JC, Toussaint JF, Zelnik V, Burny A, Kettmann R, Willems L: Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase. J Virol. 2002 Feb;76(3):1400-14.</reference_text>
      <pubmed_id>11773414</pubmed_id>
    </reference>
    <reference>
      <reference_text>Wang X, Hinson ER, Cresswell P: The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe. 2007 Aug 16;2(2):96-105.</reference_text>
      <pubmed_id>18005724</pubmed_id>
    </reference>
    <reference>
      <reference_text>Szkopinska A, Plochocka D: Farnesyl diphosphate synthase; regulation of product specificity.  Acta Biochim Pol. 2005;52(1):45-55.</reference_text>
      <pubmed_id>15827605</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009 Aug 14;325(5942):834-40. Epub 2009 Jul 16.</reference_text>
      <pubmed_id>19608861</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73.</reference_text>
      <pubmed_id>16892359</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U: The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7829-34. Epub 2006 May 9.</reference_text>
      <pubmed_id>16684881</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang Y, Cao R, Yin F, Hudock MP, Guo RT, Krysiak K, Mukherjee S, Gao YG, Robinson H, Song Y, No JH, Bergan K, Leon A, Cass L, Goddard A, Chang TK, Lin FY, Van Beek E, Papapoulos S, Wang AH, Kubo T, Ochi M, Mukkamala D, Oldfield E: Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. J Am Chem Soc. 2009 Apr 15;131(14):5153-62.</reference_text>
      <pubmed_id>19309137</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Geranyl-PP</name>
        <accession>HMDB01285</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pamidronate</name>
        <accession>HMDB14427</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pamidronate</name>
        <accession>HMDB14427</accession>
      </metabolite>
      <reference>
        <reference_text>Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.  Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.</reference_text>
        <pubmed_id>10620343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pamidronate</name>
        <accession>HMDB14427</accession>
      </metabolite>
      <reference>
        <reference_text>Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.</reference_text>
        <pubmed_id>11160603</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pamidronate</name>
        <accession>HMDB14427</accession>
      </metabolite>
      <reference>
        <reference_text>Notarnicola M, Messa C, Cavallini A, Bifulco M, Tecce MF, Eletto D, Di Leo A, Montemurro S, Laezza C, Caruso MG: Higher farnesyl diphosphate synthase activity in human colorectal cancer inhibition of cellular apoptosis. Oncology. 2004;67(5-6):351-8.</reference_text>
        <pubmed_id>15713990</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pamidronate</name>
        <accession>HMDB14427</accession>
      </metabolite>
      <reference>
        <reference_text>Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC: The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer. 2002 Jul 29;87(3):366-71.</reference_text>
        <pubmed_id>12177810</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pamidronate</name>
        <accession>HMDB14427</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang PL, Lun M, Siegelmann-Danieli N, Blasick TM, Brown RE: Pamidronate resistance and associated low ras levels in breast cancer cells: a role for combinatorial therapy. Ann Clin Lab Sci. 2004 Summer;34(3):263-70.</reference_text>
        <pubmed_id>15487700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zoledronate</name>
        <accession>HMDB14543</accession>
      </metabolite>
      <reference>
        <reference_text>Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.</reference_text>
        <pubmed_id>11160603</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zoledronate</name>
        <accession>HMDB14543</accession>
      </metabolite>
      <reference>
        <reference_text>Glickman JF, Schmid A: Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay. Assay Drug Dev Technol. 2007 Apr;5(2):205-14.</reference_text>
        <pubmed_id>17477829</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zoledronate</name>
        <accession>HMDB14543</accession>
      </metabolite>
      <reference>
        <reference_text>Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases.  Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29.</reference_text>
        <pubmed_id>17535895</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zoledronate</name>
        <accession>HMDB14543</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ibandronate</name>
        <accession>HMDB14848</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ibandronate</name>
        <accession>HMDB14848</accession>
      </metabolite>
      <reference>
        <reference_text>Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis.  Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238.</reference_text>
        <pubmed_id>16932286</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ibandronate</name>
        <accession>HMDB14848</accession>
      </metabolite>
      <reference>
        <reference_text>Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.</reference_text>
        <pubmed_id>11160603</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ibandronate</name>
        <accession>HMDB14848</accession>
      </metabolite>
      <reference>
        <reference_text>Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73.</reference_text>
        <pubmed_id>16892359</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.  Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.</reference_text>
        <pubmed_id>10620343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58.</reference_text>
        <pubmed_id>16006204</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.</reference_text>
        <pubmed_id>11160603</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64.</reference_text>
        <pubmed_id>16835450</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Risedronate</name>
        <accession>HMDB15022</accession>
      </metabolite>
      <reference>
        <reference_text>Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57.</reference_text>
        <pubmed_id>18056045</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
